�ݺ�ߣ

WÖRWAG R&D GmbH - Company profile for products to licence
out

Wörwag Research and Development GmbH
A subsidiary of the Wörwag Pharma Group dedicated to the development of:
● Generic
● OTC
● NCE products and
● Medical devices
according to European guidelines

Mission
● Provide excellent products right in time for launch with maximum therapeutic
benefit for our patients

March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com

out

Wörwag Research and Development GmbH

Business model
● Licensing-out developments done by Wörwag R&D in Europe and Worldwide
on a national, European or worldwide basis.

Please find Wörwag R&D’s current development list and compiled / approved
dossiers on the following pages or on our homepage:

www.woerwag-rd.com


WÖRWAG R&D GmbH - Company profile for products to licence out
(I)
Readily Compiled Dossiers (I):

Following dossiers are readily compiled and have received German and selected
European Marketing Authorisations. They are ready for submission in other
markets:

● Clopidogrel film coated tablets (75 mg); Original: Plavix, Iscover
● Candesartan tablets (2 | 4 | 8 | 16 | 32 mg), Original: Atacand
● Donepezil film coated tablets (5 | 10 mg), Original: Aricept
● Levetiracetam film coated tablets (250 | 500 | 750 | 1000 mg), Original:
Keppra
● Pioglitazon tablets (15 | 30 | 45 mg), Original: Actos of German origin
(Bulk and Packaging)


(II)
Readily Compiled Dossiers (II):

● Valsartan tablets (40 | 80 | 160 | 320 mg), Original: Diovan of German
origin (Bulk and Packaging)
● Losartan film coated tablets (12,5 | 25 | 50 | 100 mg); Original: Lorzaar
● Losartan-HCT film coated tablets (50/12,5 | 100/12,5 | 100/25 mg);
Original: Lorzaar Plus


(III)
Readily Compiled Dossiers (III):

● Torasemid tablets (2,5 | 5 | 10 | 20 | 200 mg); Original: Torem, Unat
● Xipamid tablets (10 | 20 | 40 mg); Original: Aquaphor
● Enalapril-HCT tablets (20/12,5 mg); Original: Benalapril Plus
● HCT tablets (12,5 | 25 mg); Original: Esidrix
● Milk Thistle Dry Extract, film coated tablets, corresponding to 150 mg
Silymarin (UV)
● Milk Thistle Dry Extract, capsules, corresponding to 86,5 mg Silymarin
(HPLC)
● Capsicum Cream (0,05 % Capsaicin), OTC product indicated for pain relief
due to chronic diabetic neuropathy
All products above are of German origin (Bulk and Packaging)

(IV)
Ongoing developments

● Candesartan-HCT tablets (8/12,5 | 16/12,5 | 32/12,5 | 32/25 mg),
Dossier ready until Q III-2011, DCP in Q IV-2011; Original: Atacand Plus
● Galantamine XR capsules (8 | 16 | 24 mg), Dossier ready,
DCP ongoing; Original: Reminyl

● Duloxetin gastro-resistant capsules (30 | 60 mg),
Dossier ready in 2012, Data protection period until Aug. 2014; Original: Cymbalta
of German origin (Bulk and Packaging)

Please find more details on our homepage at:
www.woerwag-rd.com


out

Contact

Wörwag R & D GmbH
Calwer Str. 7
D-71034 Böblingen
Germany

Dr. Wolfgang Bäurle
Head Business Development

Tel.: +49 7031-6204-794
Fax: +49 7031-6204-72
E-mail: Wolfgang.Baeurle@woerwagpharma.com
Internet: www.woerwag-rd.com

March 2011 I Wörwag R&D I Business Development I Dr. Wolfgang Bäurle www.woerwag-rd.com

�ݺ�ߣ

Woerwag RD presentation

More Related Content

Similar to Woerwag RD presentation (9)

More from Generic Pharma 2.0 (20)

Recently uploaded (20)

Woerwag RD presentation